

Sotirios Tsimikas

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2315353/publications.pdf>

Version: 2024-02-01

282
papers

25,192
citations

3515

90
h-index

8370

147
g-index

288
all docs

288
docs citations

288
times ranked

17910
citing authors

#	ARTICLE	IF	CITATIONS
1	A Test in Context: Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2017, 69, 692-711.	1.2	668
2	Oxidized Phospholipids, Lp(a) Lipoprotein, and Coronary Artery Disease. <i>New England Journal of Medicine</i> , 2005, 353, 46-57.	13.9	636
3	Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials. <i>Lancet, The</i> , 2016, 388, 2239-2253.	6.3	584
4	Lipoprotein(a) Reduction in Persons with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2020, 382, 244-255.	13.9	559
5	Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity. <i>Circulation Research</i> , 2011, 108, 235-248.	2.0	527
6	Regulated Accumulation of Desmosterol Integrates Macrophage Lipid Metabolism and Inflammatory Responses. <i>Cell</i> , 2012, 151, 138-152.	13.5	487
7	Cardiovascular and Metabolic Effects of <i>ANGPTL3</i> Antisense Oligonucleotides. <i>New England Journal of Medicine</i> , 2017, 377, 222-232.	13.9	482
8	Complement factor H binds malondialdehyde epitopes and protects from oxidative stress. <i>Nature</i> , 2011, 478, 76-81.	13.7	469
9	Atherogenic Lipids and Lipoproteins Trigger CD36-TLR2-Dependent Apoptosis in Macrophages Undergoing Endoplasmic Reticulum Stress. <i>Cell Metabolism</i> , 2010, 12, 467-482.	7.2	397
10	Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans. <i>Circulation</i> , 2016, 134, 611-624.	1.6	396
11	Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study. <i>Lancet, The</i> , 2015, 386, 1472-1483.	6.3	386
12	Oxidized phospholipids are proinflammatory and proatherogenic in hypercholesterolaemic mice. <i>Nature</i> , 2018, 558, 301-306.	13.7	359
13	Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome. <i>New England Journal of Medicine</i> , 2019, 381, 531-542.	13.9	359
14	Baseline and on-statin treatment lipoprotein(a) levels for prediction of cardiovascular events: individual patient-data meta-analysis of statin outcome trials. <i>Lancet, The</i> , 2018, 392, 1311-1320.	6.3	355
15	NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 177-192.	1.2	337
16	Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. <i>Journal of the American College of Cardiology</i> , 2003, 41, 360-370.	1.2	310
17	Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. <i>Journal of the American College of Cardiology</i> , 2020, 75, 133-144.	1.2	296
18	C-Reactive Protein and Other Emerging Blood Biomarkers to Optimize Risk Stratification of Vulnerable Patients. <i>Journal of the American College of Cardiology</i> , 2006, 47, C19-C31.	1.2	295

#	ARTICLE	IF	CITATIONS
19	Oxidized Phospholipids, Lipoprotein(a), and Progression of Calcific Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2015, 66, 1236-1246.	1.2	295
20	A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. <i>Journal of Lipid Research</i> , 2008, 49, 2230-2239.	2.0	290
21	Statin therapy increases lipoprotein(a) levels. <i>European Heart Journal</i> , 2020, 41, 2275-2284.	1.0	265
22	Clinical utility of inflammatory markers and advanced lipoprotein testing: Advice from an expert panel of lipid specialists. <i>Journal of Clinical Lipidology</i> , 2011, 5, 338-367.	0.6	235
23	Discrimination and Net Reclassification of Cardiovascular Risk With Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2014, 64, 851-860.	1.2	231
24	Percutaneous Coronary Intervention Results in Acute Increases in Oxidized Phospholipids and Lipoprotein(a). <i>Circulation</i> , 2004, 109, 3164-3170.	1.6	229
25	Oxidized Phospholipids, Lipoprotein(a), Lipoprotein-Associated Phospholipase A2 Activity, and 10-Year Cardiovascular Outcomes. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 1788-1795.	1.1	220
26	Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. <i>Journal of Lipid Research</i> , 2007, 48, 425-433.	2.0	215
27	The role of oxidized phospholipids in atherosclerosis. <i>Journal of Lipid Research</i> , 2009, 50, S207-S212.	2.0	213
28	High-Dose Atorvastatin Reduces Total Plasma Levels of Oxidized Phospholipids and Immune Complexes Present on Apolipoprotein B-100 in Patients With Acute Coronary Syndromes in the MIRACL Trial. <i>Circulation</i> , 2004, 110, 1406-1412.	1.6	209
29	Human-Derived Anti-Oxidized LDL Autoantibody Blocks Uptake of Oxidized LDL by Macrophages and Localizes to Atherosclerotic Lesions In Vivo. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 1333-1339.	1.1	197
30	Lipoprotein(a) as a Potential Causal Genetic Risk Factor of Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2012, 60, 716-721.	1.2	190
31	Vupanorsen, an N-acetyl galactosamine-conjugated antisense drug to <i>ANGPTL3</i> mRNA, lowers triglycerides and atherogenic lipoproteins in patients with diabetes, hepatic steatosis, and hypertriglyceridaemia. <i>European Heart Journal</i> , 2020, 41, 3936-3945.	1.0	188
32	Oxidation-Specific Biomarkers, Prospective 15-Year Cardiovascular and Stroke Outcomes, and Net Reclassification of Cardiovascular Events. <i>Journal of the American College of Cardiology</i> , 2012, 60, 2218-2229.	1.2	187
33	Lipoprotein(a) and Oxidized Phospholipids Promote Valve Calcification in Patients With Aortic Stenosis. <i>Journal of the American College of Cardiology</i> , 2019, 73, 2150-2162.	1.2	187
34	Oxidized Phospholipids Predict the Presence and Progression of Carotid and Femoral Atherosclerosis and Symptomatic Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2219-2228.	1.2	174
35	Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a). <i>Journal of Lipid Research</i> , 2013, 54, 2815-2830.	2.0	174
36	Leucocyte Telomere Length and Risk of Type 2 Diabetes Mellitus: New Prospective Cohort Study and Literature-Based Meta-Analysis. <i>PLoS ONE</i> , 2014, 9, e112483.	1.1	174

#	ARTICLE	IF	CITATIONS
37	Targeted Molecular Probes for Imaging Atherosclerotic Lesions With Magnetic Resonance Using Antibodies That Recognize Oxidation-Specific Epitopes. <i>Circulation</i> , 2008, 117, 3206-3215.	1.6	170
38	Deficiency of Glutathione Peroxidase-1 Accelerates the Progression of Atherosclerosis in Apolipoprotein E-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 850-857.	1.1	169
39	Mipomersen, an Antisense Oligonucleotide to Apolipoprotein B-100, Reduces Lipoprotein(a) in Various Populations With Hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 689-699.	1.1	165
40	Apolipoprotein(a) isoform size, lipoprotein(a) concentration, and coronary artery disease: a mendelian randomisation analysis. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 524-533.	5.5	165
41	Adaptive immunity in atherogenesis: new insights and therapeutic approaches. <i>Journal of Clinical Investigation</i> , 2013, 123, 27-36.	3.9	163
42	N-acetyl galactosamine-conjugated antisense drug to APOC3 mRNA, triglycerides and atherogenic lipoprotein levels. <i>European Heart Journal</i> , 2019, 40, 2785-2796.	1.0	159
43	Oxidized phospholipids on apoB-100-containing lipoproteins: a biomarker predicting cardiovascular disease and cardiovascular events. <i>Biomarkers in Medicine</i> , 2011, 5, 673-694.	0.6	156
44	Patients With High Genome-Wide Polygenic Risk Scores for Coronary Artery Disease May Receive Greater Clinical Benefit From Alirocumab Treatment in the ODYSSEY OUTCOMES Trial. <i>Circulation</i> , 2020, 141, 624-636.	1.6	155
45	The Severe Hypercholesterolemia Phenotype. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1935-1947.	1.2	153
46	Lipoprotein(a) for Risk Assessment in Patients With Established Coronary Artery Disease. <i>Journal of the American College of Cardiology</i> , 2014, 63, 520-527.	1.2	152
47	Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III. <i>Journal of the American College of Cardiology</i> , 2017, 69, 789-800.	1.2	150
48	Oxidative Modification of Lipoproteins: Mechanisms, Role in Inflammation and Potential Clinical Applications in Cardiovascular Disease. <i>Current Pharmaceutical Design</i> , 2011, 17, 27-37.	0.9	148
49	Circulating Autoantibodies to Oxidized LDL Correlate With Arterial Accumulation and Depletion of Oxidized LDL in LDL Receptor-Deficient Mice. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2001, 21, 95-100.	1.1	147
50	Lipoprotein(a) and Risk of Coronary, Cerebrovascular, and Peripheral Artery Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 3058-3065.	1.1	146
51	Apolipoprotein C-III: From Pathophysiology to Pharmacology. <i>Trends in Pharmacological Sciences</i> , 2015, 36, 675-687.	4.0	144
52	Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice. <i>Circulation</i> , 2008, 118, 743-753.	1.6	143
53	New Insights Into the Role of Lipoprotein(a)-Associated Lipoprotein-Associated Phospholipase A ₂ in Atherosclerosis and Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 2094-2099.	1.1	140
54	Oxidation-Specific Biomarkers, Lipoprotein(a), and Risk of Fatal and Nonfatal Coronary Events. <i>Journal of the American College of Cardiology</i> , 2010, 56, 946-955.	1.2	139

#	ARTICLE	IF	CITATIONS
55	Prevalence of Elevated Lp(a) Mass Levels and Patient Thresholds in 532 359 Patients in the United States. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2016, 36, 2239-2245.	1.1	132
56	Clinical applications of circulating oxidized low-density lipoprotein biomarkers in cardiovascular disease. <i>Current Opinion in Lipidology</i> , 2006, 17, 502-509.	1.2	131
57	Differential expression of oxidation-specific epitopes and apolipoprotein(a) in progressing and ruptured human coronary and carotid atherosclerotic lesions. <i>Journal of Lipid Research</i> , 2012, 53, 2773-2790.	2.0	131
58	Aged garlic extract supplemented with B vitamins, folic acid and l-arginine retards the progression of subclinical atherosclerosis: A randomized clinical trial. <i>Preventive Medicine</i> , 2009, 49, 101-107.	1.6	129
59	Common femoral artery anatomy is influenced by demographics and comorbidity: Implications for cardiac and peripheral invasive studies. <i>Catheterization and Cardiovascular Interventions</i> , 2001, 53, 289-295.	0.7	124
60	Lipid-Lowering Agents. <i>Circulation Research</i> , 2019, 124, 386-404.	2.0	124
61	Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. <i>Journal of Nuclear Cardiology</i> , 1999, 6, 41-53.	1.4	122
62	The role of innate immunity in atherogenesis. <i>Journal of Lipid Research</i> , 2009, 50, S388-S393.	2.0	122
63	LDL-C and LDL-C+Lp(a)-C. <i>Current Opinion in Lipidology</i> , 2015, 26, 169-178.	1.2	122
64	Measuring Circulating Oxidized Low-Density Lipoprotein to Evaluate Coronary Risk. <i>Circulation</i> , 2001, 103, 1930-1932.	1.6	121
65	In Vivo Uptake of Radiolabeled MDA2, an Oxidation-Specific Monoclonal Antibody, Provides an Accurate Measure of Atherosclerotic Lesions Rich in Oxidized LDL and Is Highly Sensitive to Their Regression. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2000, 20, 689-697.	1.1	119
66	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 Particles to Race/Ethnicity, Apolipoprotein(a) Isoform Size, and Cardiovascular Risk Factors. <i>Circulation</i> , 2009, 119, 1711-1719.	1.6	117
67	Lipoprotein(a) lowering by alirocumab reduces the total burden of cardiovascular events independent of low-density lipoprotein cholesterol lowering: ODYSSEY OUTCOMES trial. <i>European Heart Journal</i> , 2020, 41, 4245-4255.	1.0	117
68	Lysine-Phosphatidylcholine Adducts in Kringle V Impart Unique Immunological and Potential Pro-inflammatory Properties to Human Apolipoprotein(a). <i>Journal of Biological Chemistry</i> , 2003, 278, 52841-52847.	1.6	116
69	Secretory Phospholipase A2-IIA and Cardiovascular Disease. <i>Journal of the American College of Cardiology</i> , 2013, 62, 1966-1976.	1.2	115
70	Antisense Oligonucleotide Lowers Plasma Levels of Apolipoprotein (a) and Lipoprotein (a) in Transgenic Mice. <i>Journal of the American College of Cardiology</i> , 2011, 57, 1611-1621.	1.2	113
71	Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. <i>Journal of Lipid Research</i> , 2011, 52, 1829-1836.	2.0	113
72	Neutralization of Oxidized Phospholipids Ameliorates Non-alcoholic Steatohepatitis. <i>Cell Metabolism</i> , 2020, 31, 189-206.e8.	7.2	113

#	ARTICLE	IF	CITATIONS
73	Antisense inhibition of apolipoprotein (a) to lower plasma lipoprotein (a) levels in humans. <i>Journal of Lipid Research</i> , 2016, 57, 340-351.	2.0	112
74	Lipoprotein Modification and Macrophage Uptake: Role of Pathologic Cholesterol Transport in Atherogenesis. <i>Sub-Cellular Biochemistry</i> , 2010, 51, 229-251.	1.0	111
75	B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. <i>Circulation Research</i> , 2015, 117, e28-39.	2.0	111
76	Pro-Inflammatory Interleukin-1 Genotypes Potentiate the Risk of Coronary Artery Disease and Cardiovascular Events Mediated by Oxidized Phospholipids and Lipoprotein(a). <i>Journal of the American College of Cardiology</i> , 2014, 63, 1724-1734.	1.2	110
77	Immunomodulatory Effects of Statins: Mechanisms and Potential Impact on Arteriosclerosis. <i>Journal of the American Society of Nephrology: JASN</i> , 2002, 13, 1673-1681.	3.0	109
78	Adenoviral intramyocardial VEGF-D ¹ N ¹ C gene transfer increases myocardial perfusion reserve in refractory angina patients: a phase I/IIa study with 1-year follow-up. <i>European Heart Journal</i> , 2017, 38, 2547-2555.	1.0	109
79	Efficacy and safety of volanesorsen in patients with multifactorial chylomicronaemia (COMPASS): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. <i>Lancet Diabetes and Endocrinology</i> , 2021, 9, 264-275.	5.5	109
80	Targeted Iron Oxide Particles for In Vivo Magnetic Resonance Detection of Atherosclerotic Lesions With Antibodies Directed to Oxidation-Specific Epitopes. <i>Journal of the American College of Cardiology</i> , 2011, 57, 337-347.	1.2	108
81	The role of oxidized phospholipids in mediating lipoprotein(a) atherogenicity. <i>Current Opinion in Lipidology</i> , 2008, 19, 369-377.	1.2	106
82	The Influence of Pravastatin and Atorvastatin on Markers of Oxidative Stress in Hypercholesterolemic Humans. <i>Journal of the American College of Cardiology</i> , 2008, 51, 1653-1662.	1.2	104
83	Long-term mipomersen treatment is associated with a reduction in cardiovascular events in patients with familial hypercholesterolemia. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1011-1021.	0.6	104
84	B-Cell Aortic Homing and Atheroprotection Depend on Id3. <i>Circulation Research</i> , 2012, 110, e1-12.	2.0	102
85	Human Oxidation-Specific Antibodies Reduce Foam Cell Formation and Atherosclerosis Progression. <i>Journal of the American College of Cardiology</i> , 2011, 58, 1715-1727.	1.2	100
86	Lipoprotein-associated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. <i>European Heart Journal</i> , 2008, 30, 107-115.	1.0	99
87	PCSK9 Association With Lipoprotein(a). <i>Circulation Research</i> , 2016, 119, 29-35.	2.0	99
88	Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. <i>Journal of Lipid Research</i> , 2015, 56, 440-448.	2.0	96
89	Atherogenic Lipoprotein(a) Increases Vascular Glycolysis, Thereby Facilitating Inflammation and Leukocyte Extravasation. <i>Circulation Research</i> , 2020, 126, 1346-1359.	2.0	96
90	Immune cell screening of a nanoparticle library improves atherosclerosis therapy. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, E6731-E6740.	3.3	95

#	ARTICLE	IF	CITATIONS
91	Invasive Cardiologists Are Exposed to Greater Left Sided Cranial Radiation. <i>JACC: Cardiovascular Interventions</i> , 2015, 8, 1197-1206.	1.1	93
92	Relationship Between Biomarkers of Oxidized Low-Density Lipoprotein, Statin Therapy, Quantitative Coronary Angiography, and Atheroma Volume. <i>Journal of the American College of Cardiology</i> , 2008, 52, 24-32.	1.2	92
93	Relationship of Oxidized Phospholipids and Biomarkers of Oxidized Low-Density Lipoprotein With Cardiovascular Risk Factors, Inflammatory Biomarkers, and Effect of Statin Therapy in Patients With Acute Coronary Syndromes. <i>Journal of the American College of Cardiology</i> , 2009, 53, 2186-2196.	1.2	91
94	Release and Capture of Bioactive Oxidized Phospholipids and Oxidized Cholesteryl Esters During Percutaneous Coronary and Peripheral Arterial Interventions in Humans. <i>Journal of the American College of Cardiology</i> , 2014, 63, 1961-1971.	1.2	88
95	Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B100 and lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2016, 10, 594-603.	0.6	88
96	Oxidative Biomarkers in the Diagnosis and Prognosis of Cardiovascular Disease. <i>American Journal of Cardiology</i> , 2006, 98, S9-S17.	0.7	87
97	Emerging RNA Therapeutics to Lower Blood Levels of Lp(a). <i>Journal of the American College of Cardiology</i> , 2021, 77, 1576-1589.	1.2	86
98	Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). <i>Journal of Lipid Research</i> , 2015, 56, 2273-2285.	2.0	85
99	Integrated Assessment of the Clinical Performance of GalNAc ₃ -Conjugated 2'-O-Methoxyethyl Chimeric Antisense Oligonucleotides: I. Human Volunteer Experience. <i>Nucleic Acid Therapeutics</i> , 2019, 29, 16-32.	2.0	85
100	Reduction in lipoprotein-associated apoC-III levels following volanesorsen therapy: phase 2 randomized trial results. <i>Journal of Lipid Research</i> , 2016, 57, 706-713.	2.0	83
101	<i>LPA</i> Gene, Ethnicity, and Cardiovascular Events. <i>Circulation</i> , 2017, 135, 251-263.	1.6	83
102	Oxidized Low-Density Lipoprotein in Children With Familial Hypercholesterolemia and Unaffected Siblings. <i>Journal of the American College of Cardiology</i> , 2006, 47, 1803-1810.	1.2	82
103	The Association Between Circulating Lipoprotein(a) and Type 2 Diabetes: Is It Causal?. <i>Diabetes</i> , 2014, 63, 332-342.	0.3	82
104	In vivo visualization and attenuation of oxidized lipid accumulation in hypercholesterolemic zebrafish. <i>Journal of Clinical Investigation</i> , 2011, 121, 4861-4869.	3.9	81
105	Reduced In Vivo Aortic Uptake of Radiolabeled Oxidation-Specific Antibodies Reflects Changes in Plaque Composition Consistent With Plaque Stabilization. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004, 24, 2307-2312.	1.1	80
106	Oxidized Cholesteryl Esters and Phospholipids in Zebrafish Larvae Fed a High Cholesterol Diet. <i>Journal of Biological Chemistry</i> , 2010, 285, 32343-32351.	1.6	80
107	Imaging Vulnerable Plaque by Ultrasound. <i>Journal of the American College of Cardiology</i> , 2006, 47, C32-C39.	1.2	79
108	Increased Plasma Oxidized Phospholipid:Apolipoprotein B-100 Ratio With Concomitant Depletion of Oxidized Phospholipids From Atherosclerotic Lesions After Dietary Lipid-Lowering. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 175-181.	1.1	78

#	ARTICLE	IF	CITATIONS
109	InÂVivo PET Imaging of HDL in MultipleÂAtherosclerosisÂModels. JACC: Cardiovascular Imaging, 2016, 9, 950-961.	2.3	78
110	Apolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk. European Heart Journal, 2022, 43, 1401-1412.	1.0	78
111	MCP-1 binds to oxidized LDL and is carried by lipoprotein(a) in human plasma. Journal of Lipid Research, 2013, 54, 1877-1883.	2.0	76
112	Lipoprotein(a) Mass Levels Increase Significantly According to <i>APOE</i> Genotype. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 580-588.	1.1	76
113	Cell-specific discrimination of desmosterol and desmosterol mimetics confers selective regulation of LXR and SREBP in macrophages. Proceedings of the National Academy of Sciences of the United States of America, 2018, 115, E4680-E4689.	3.3	76
114	Association of Mild to Moderate Aortic Valve Stenosis Progression With Higher Lipoprotein(a) and Oxidized Phospholipid Levels. JAMA Cardiology, 2018, 3, 1212.	3.0	76
115	Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. Current Opinion in Pharmacology, 2013, 13, 168-179.	1.7	74
116	Pioglitazone Modulates Vascular Inflammation in Atherosclerotic Rabbits. JACC: Cardiovascular Imaging, 2011, 4, 1100-1109.	2.3	73
117	Oxidized low-density lipoprotein biomarkers in atherosclerosis. Current Atherosclerosis Reports, 2006, 8, 55-61.	2.0	71
118	Oxidation-Specific Biomarkers and Risk of Peripheral Artery Disease. Journal of the American College of Cardiology, 2013, 61, 2169-2179.	1.2	71
119	Protective Role for B-1b B Cells and IgM in Obesity-Associated Inflammation, Glucose Intolerance, and Insulin Resistance. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 682-691.	1.1	69
120	Regression of Inflammation in Atherosclerosis by the LXR Agonist R211945. JACC: Cardiovascular Imaging, 2012, 5, 819-828.	2.3	68
121	Noninvasive imaging of atherosclerotic lesions in apolipoprotein E-deficient and low-density-lipoprotein receptor-deficient mice with annexin A5. Journal of Nuclear Medicine, 2006, 47, 1497-505.	2.8	68
122	Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. Journal of Lipid Research, 2010, 51, 3324-3330.	2.0	67
123	Lipoprotein(a) and incident type-2 diabetes: results from the prospective Bruneck study and a meta-analysis of published literature. Cardiovascular Diabetology, 2017, 16, 38.	2.7	66
124	Relationship of lipoprotein(a) molar concentrations and mass according to lipoprotein(a) thresholds and apolipoprotein(a) isoform size. Journal of Clinical Lipidology, 2018, 12, 1313-1323.	0.6	66
125	Nanobody-Facilitated Multiparametric PET/MRI Phenotyping of Atherosclerosis. JACC: Cardiovascular Imaging, 2019, 12, 2015-2026.	2.3	66
126	Potent lipoprotein(a) lowering following apolipoprotein(a) antisense treatment reduces the pro-inflammatory activation of circulating monocytes in patients with elevated lipoprotein(a). European Heart Journal, 2020, 41, 2262-2271.	1.0	65

#	ARTICLE	IF	CITATIONS
127	Effect of Pelacarsen on Lipoprotein(a) Cholesterol and Corrected Low-Density Lipoprotein Cholesterol. <i>Journal of the American College of Cardiology</i> , 2022, 79, 1035-1046.	1.2	65
128	Oxidized Low-Density Lipoprotein Autoantibodies, Chronic Infections, and Carotid Atherosclerosis in a Population-Based Study. <i>Journal of the American College of Cardiology</i> , 2006, 47, 2436-2443.	1.2	64
129	Oxidized Phospholipids Are Present on Plasminogen, Affect Fibrinolysis, and Increase Following Acute Myocardial Infarction. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1426-1437.	1.2	64
130	Novel method for quantification of lipoprotein(a)-cholesterol: implications for improving accuracy of LDL-C measurements. <i>Journal of Lipid Research</i> , 2021, 62, 100053.	2.0	62
131	In Vivo Markers of Oxidative Stress and Therapeutic Interventions. <i>American Journal of Cardiology</i> , 2008, 101, S34-S42.	0.7	61
132	Relationship of Oxidized Phospholipids on Apolipoprotein B-100 to Cardiovascular Outcomes in Patients Treated With Intensive Versus Moderate Atorvastatin Therapy. <i>Journal of the American College of Cardiology</i> , 2015, 65, 1286-1295.	1.2	61
133	Lipoprotein(a)-Associated Molecules Are Prominent Components in Plasma and Valve Leaflets in Calcific Aortic Valve Stenosis. <i>JACC Basic To Translational Science</i> , 2017, 2, 229-240.	1.9	61
134	Reduction of myocardial ischaemia-reperfusion injury by inactivating oxidized phospholipids. <i>Cardiovascular Research</i> , 2019, 115, 179-189.	1.8	61
135	Oxidized Phospholipids and Risk of Calcific Aortic Valve Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1570-1578.	1.1	60
136	Relation of Oxidative Biomarkers, Vascular Dysfunction, and Progression of Coronary Artery Calcium. <i>American Journal of Cardiology</i> , 2010, 105, 459-466.	0.7	59
137	From traditional pharmacological towards nucleic acid-based therapies for cardiovascular diseases. <i>European Heart Journal</i> , 2020, 41, 3884-3899.	1.0	58
138	Potential Causality and Emerging Medical Therapies for Lipoprotein(a) and Its Associated Oxidized Phospholipids in Calcific Aortic Valve Stenosis. <i>Circulation Research</i> , 2019, 124, 405-415.	2.0	57
139	Emerging therapeutic agents to lower lipoprotein (a) levels. <i>Current Opinion in Lipidology</i> , 2012, 23, 560-568.	1.2	56
140	Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1206-1212.	1.1	56
141	In Vivo Detection of Oxidation-Specific Epitopes in Atherosclerotic Lesions Using Biocompatible Manganese Molecular Magnetic Imaging Probes. <i>Journal of the American College of Cardiology</i> , 2012, 59, 616-626.	1.2	55
142	Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis. <i>Current Opinion in Cardiology</i> , 2016, 31, 440-450.	0.8	55
143	The Effects of 2'-O-Methoxyethyl Oligonucleotides on Renal Function in Humans. <i>Nucleic Acid Therapeutics</i> , 2018, 28, 10-22.	2.0	55
144	Lipoprotein(a) and Its Potential Association with Thrombosis and Inflammation in COVID-19: a Testable Hypothesis. <i>Current Atherosclerosis Reports</i> , 2020, 22, 48.	2.0	55

#	ARTICLE	IF	CITATIONS
145	RNA-targeted therapeutics for lipid disorders. <i>Current Opinion in Lipidology</i> , 2018, 29, 459-466.	1.2	54
146	Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. <i>Journal of Lipid Research</i> , 2012, 53, 1670-1678.	2.0	53
147	Relationship between "LDL-C", estimated true LDL-C, apolipoprotein B-100, and PCSK9 levels following lipoprotein(a) lowering with an antisense oligonucleotide. <i>Journal of Clinical Lipidology</i> , 2018, 12, 702-710.	0.6	53
148	High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. <i>Journal of Lipid Research</i> , 2005, 46, 769-778.	2.0	52
149	The dedicated "Lp(a) clinic" A concept whose time has arrived?. <i>Atherosclerosis</i> , 2020, 300, 1-9.	0.4	52
150	Phospholipase A Enzymes, High-Dose Atorvastatin, and Prediction of Ischemic Events After Acute Coronary Syndromes. <i>Circulation</i> , 2012, 125, 757-766.	1.6	51
151	Noninvasive imaging of oxidized Low-Density Lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. <i>American Journal of Cardiology</i> , 2002, 90, L22-L27.	0.7	50
152	Relationship of Autoantibodies to MDA-LDL and ApoB-Immune Complexes to Sex, Ethnicity, Subclinical Atherosclerosis, and Cardiovascular Events. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2017, 37, 1213-1221.	1.1	50
153	Heme Oxygenase-1 Gene Promoter Microsatellite Polymorphism Is Associated With Progressive Atherosclerosis and Incident Cardiovascular Disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 229-236.	1.1	49
154	Lipoprotein(a). <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2016, 23, 157-164.	1.2	49
155	Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine. <i>Journal of Lipid Research</i> , 2014, 55, 2137-2155.	2.0	47
156	Helix-Loop-Helix Factor Inhibitor of Differentiation 3 Regulates Interleukin-5 Expression and B-1a B Cell Proliferation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2013, 33, 2771-2779.	1.1	46
157	Oxidized Phospholipids on Apolipoprotein B-100 and Recurrent Ischemic Events Following Stroke or Transient Ischemic Attack. <i>Journal of the American College of Cardiology</i> , 2017, 69, 147-158.	1.2	46
158	Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. <i>Journal of Lipid Research</i> , 2012, 53, 1316-1326.	2.0	44
159	Polyoxygenated Cholesterol Ester Hydroperoxide Activates TLR4 and SYK Dependent Signaling in Macrophages. <i>PLoS ONE</i> , 2013, 8, e83145.	1.1	44
160	Heritability of Biomarkers of Oxidized Lipoproteins. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, 1704-1711.	1.1	44
161	Ligand conjugated antisense oligonucleotide for the treatment of transthyretin amyloidosis: preclinical and phase 1 data. <i>ESC Heart Failure</i> , 2021, 8, 652-661.	1.4	43
162	Diversification and CXCR4-Dependent Establishment of the Bone Marrow B-1a Cell Pool Governs Atheroprotective IgM Production Linked to Human Coronary Atherosclerosis. <i>Circulation Research</i> , 2019, 125, e55-e70.	2.0	42

#	ARTICLE	IF	CITATIONS
163	Measures of Oxidative Stress. <i>Clinics in Laboratory Medicine</i> , 2006, 26, 571-590.	0.7	41
164	Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. <i>Atherosclerosis</i> , 2013, 226, 161-164.	0.4	41
165	Oxidation-specific epitopes restrain bone formation. <i>Nature Communications</i> , 2018, 9, 2193.	5.8	41
166	PET/MR Imaging of Malondialdehyde-Acetaldehyde Epitopes With a Human Antibody Detects Clinically Relevant Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2018, 71, 321-335.	1.2	39
167	New Therapeutic Targets for Calcific Aortic Valve Stenosis. <i>Journal of the American College of Cardiology</i> , 2014, 63, 478-480.	1.2	38
168	Lipoprotein(a), Oxidized Phospholipids, and Aortic Valve Microcalcification Assessed by 18F-Sodium Fluoride Positron Emission Tomography and Computed Tomography. <i>CJC Open</i> , 2019, 1, 131-140.	0.7	38
169	Severe ostial saphenous vein graft disease leading to acute coronary syndromes following proximal aorto-saphenous anastomoses with the symmetry bypass connector device. <i>Journal of the American College of Cardiology</i> , 2004, 43, 133-139.	1.2	36
170	The I4399M variant of apolipoprotein(a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. <i>Atherosclerosis</i> , 2010, 209, 498-503.	0.4	36
171	Increased Expression of Oxidation-Specific Epitopes and Apoptosis Are Associated With Haptoglobin Genotype. <i>Journal of the American College of Cardiology</i> , 2012, 60, 112-119.	1.2	36
172	Temporal variability in lipoprotein(a) levels in patients enrolled in the placebo arms of IONIS-APO(a)Rx and IONIS-APO(a)-LRx antisense oligonucleotide clinical trials. <i>Journal of Clinical Lipidology</i> , 2018, 12, 122-129.e2.	0.6	36
173	Potent reduction of plasma lipoprotein (a) with an antisense oligonucleotide in human subjects does not affect ex vivo fibrinolysis. <i>Journal of Lipid Research</i> , 2019, 60, 2082-2089.	2.0	35
174	Design and Rationale of the Global Phase 3 NEURO-TTRansform Study of Antisense Oligonucleotide AKCEA-TTR-LRx (ION-682884-CS3) in Hereditary Transthyretin-Mediated Amyloid Polyneuropathy. <i>Neurology and Therapy</i> , 2021, 10, 375-389.	1.4	34
175	Oxidized Phospholipids Promote NETosis and Arterial Thrombosis in LNK(SH2B3) Deficiency. <i>Circulation</i> , 2021, 144, 1940-1954.	1.6	33
176	Effect of an oral astaxanthin prodrug (CDX-085) on lipoprotein levels and progression of atherosclerosis in LDLR ^{-/-} and ApoE ^{-/-} mice. <i>Atherosclerosis</i> , 2012, 222, 99-105.	0.4	32
177	Oxidation-specific epitopes as targets for biotheranostic applications in humans. <i>Current Opinion in Lipidology</i> , 2013, 24, 426-437.	1.2	31
178	Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis. <i>Cardiovascular Drugs and Therapy</i> , 2016, 30, 75-85.	1.3	31
179	Lipoprotein(a) Improves Cardiovascular Risk Prediction Based on Established Risk Algorithms. <i>Journal of the American College of Cardiology</i> , 2017, 69, 1513-1515.	1.2	31
180	Relationship of a comprehensive panel of plasma oxidized low-density lipoprotein markers to angiographic restenosis in patients undergoing percutaneous coronary intervention for stable angina. <i>American Heart Journal</i> , 2005, 150, 1007-1014.	1.2	30

#	ARTICLE	IF	CITATIONS
181	Identification of a novel series of anti-inflammatory and anti-oxidative phospholipid oxidation products containing the cyclopentenone moiety in vitro and in vivo: Implication in atherosclerosis. <i>Journal of Biological Chemistry</i> , 2017, 292, 5378-5391.	1.6	30
182	Antisense Inhibition of Angiotensinogen With IONIS-AGT-LRx. <i>JACC Basic To Translational Science</i> , 2021, 6, 485-496.	1.9	30
183	Threshold Effects of Circulating Angiopoietin-Like 3 Levels on Plasma Lipoproteins. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2017, 102, 3340-3348.	1.8	29
184	Genome-Wide Association Study Highlights <i>APOH</i> as a Novel Locus for Lipoprotein(a) Levels. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2021, 41, 458-464.	1.1	29
185	microRNA-483 ameliorates hypercholesterolemia by inhibiting PCSK9 production. <i>JCI Insight</i> , 2020, 5, .	2.3	29
186	Consequences of Cholesteryl Ester Transfer Protein Inhibition in Patients With Familial Hypoalphalipoproteinemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005, 25, e133-4.	1.1	28
187	Circulating levels of plasminogen and oxidized phospholipids bound to plasminogen distinguish between atherothrombotic and non-atherothrombotic myocardial infarction. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 42, 61-76.	1.0	28
188	ApoCIII-Lp(a) complexes in conjunction with Lp(a)-OxPL predict rapid progression of aortic stenosis. <i>Heart</i> , 2020, 106, 738-745.	1.2	28
189	Lipoprotein(a), venous thromboembolism and COVID-19: A pilot study. <i>Atherosclerosis</i> , 2022, 341, 43-49.	0.4	28
190	Imaging of Oxidation-Specific Epitopes in Atherosclerosis and Macrophage-Rich Vulnerable Plaques. <i>Current Cardiovascular Imaging Reports</i> , 2011, 4, 4-16.	0.4	27
191	Lipid Oxidation in Carriers of Lecithin:Cholesterol Acyltransferase Gene Mutations. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2012, 32, 3066-3075.	1.1	27
192	Low-Density Lipoprotein Cholesterol Corrected for Lipoprotein(a) Cholesterol, Risk Thresholds, and Cardiovascular Events. <i>Journal of the American Heart Association</i> , 2020, 9, e016318.	1.6	26
193	The role of oxidized phospholipids, lipoprotein (a) and biomarkers of oxidized lipoproteins in chronically occluded coronary arteries in sudden cardiac death and following successful percutaneous revascularization. <i>Cardiovascular Revascularization Medicine</i> , 2012, 13, 11-19.	0.3	25
194	Manganese G8 dendrimers targeted to oxidation-specific epitopes: In vivo MR imaging of atherosclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2015, 41, 797-805.	1.9	25
195	The re-emergence of lipoprotein(a) in a broader clinical arena. <i>Progress in Cardiovascular Diseases</i> , 2016, 59, 135-144.	1.6	24
196	Population and assay thresholds for the predictive value of lipoprotein (a) for coronary artery disease: the EPIC-Norfolk Prospective Population Study. <i>Journal of Lipid Research</i> , 2016, 57, 697-705.	2.0	24
197	Atherothrombotic factors and atherosclerotic cardiovascular events: the multi-ethnic study of atherosclerosis. <i>European Heart Journal</i> , 2022, 43, 971-981.	1.0	23
198	What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?. <i>Current Opinion in Lipidology</i> , 2014, 25, 423-430.	1.2	22

#	ARTICLE	IF	CITATIONS
199	The Oxidative Modification Hypothesis of Atherogenesis. <i>Developments in Cardiovascular Medicine</i> , 2000, , 49-74.	0.1	22
200	Lipoprotein(a)-cholesterol levels estimated by vertical auto profile correlate poorly with Lp(a) mass in hyperlipidemic subjects: Implications for clinical practice interpretation of Lp(a)-mediated risk. <i>Journal of Clinical Lipidology</i> , 2016, 10, 1389-1396.	0.6	20
201	Statins and increases in Lp(a): an inconvenient truth that needs attention. <i>European Heart Journal</i> , 2020, 41, 192-193.	1.0	20
202	Prevalence and influence of LPA gene variants and isoform size on the Lp(a)-lowering effect of pelacarsen. <i>Atherosclerosis</i> , 2021, 324, 102-108.	0.4	19
203	Non-invasive imaging of vulnerable plaques by molecular targeting of oxidized LDL with tagged oxidation-specific antibodies. <i>Journal of Cellular Biochemistry</i> , 2002, 87, 138-146.	1.2	18
204	Lipoprotein(a) accelerates atherosclerosis in uremic mice. <i>Journal of Lipid Research</i> , 2010, 51, 2967-2975.	2.0	18
205	Imaging of Oxidation-Specific Epitopes with Targeted Nanoparticles to Detect High-Risk Atherosclerotic Lesions: Progress and Future Directions. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 719-736.	1.1	18
206	Interleukin-1 genotypes modulate the long-term effect of lipoprotein(a) on cardiovascular events: The Ioannina Study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 338-347.	0.6	18
207	The challenges of measuring Lp(a): A fight against Hydra?. <i>Atherosclerosis</i> , 2019, 289, 181-183.	0.4	18
208	Intracellular AIBP (Apolipoprotein A-I Binding Protein) Regulates Oxidized LDL (Low-Density) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 387 T 2021, 41, e82-e96.	1.1	18
209	Plasma Proteomics for Epidemiology. <i>Circulation: Cardiovascular Genetics</i> , 2017, 10, .	5.1	17
210	Neutralization of oxidized phospholipids attenuates age-associated bone loss in mice. <i>Aging Cell</i> , 2021, 20, e13442.	3.0	17
211	Prevalence of coronary artery spasm after stent placement and its association with inflammation. <i>International Journal of Cardiology</i> , 2015, 179, 252-255.	0.8	16
212	In search of a physiological function of lipoprotein(a): causality of elevated Lp(a) levels and reduced incidence of type 2 diabetes. <i>Journal of Lipid Research</i> , 2018, 59, 741-744.	2.0	16
213	Oxidized Low-Density Lipoprotein Biomarkers in Patients with End-Stage Renal Failure: Acute Effects of Hemodialysis. <i>Blood Purification</i> , 2007, 25, 457-465.	0.9	15
214	The Evolution of Thienopyridine Therapy. <i>Journal of the American College of Cardiology</i> , 2008, 51, 2228-2229.	1.2	15
215	Acute and long-term effect of percutaneous coronary intervention on serially-measured oxidative, inflammatory, and coagulation biomarkers in patients with stable angina. <i>Journal of Thrombosis and Thrombolysis</i> , 2016, 41, 569-580.	1.0	15
216	Effect of olezarsen targeting APOC-III on lipoprotein size and particle number measured by NMR in patients with hypertriglyceridemia. <i>Journal of Clinical Lipidology</i> , 2022, 16, 617-625.	0.6	15

#	ARTICLE	IF	CITATIONS
217	Lipoprotein-associated phospholipase A2 mass and activity in children with heterozygous familial hypercholesterolemia and unaffected siblings: Effect of pravastatin. <i>Journal of Clinical Lipidology</i> , 2011, 5, 50-56.	0.6	14
218	Novel Lipoprotein(a) Catabolism Pathway via Apolipoprotein(a) Recycling. <i>Circulation Research</i> , 2017, 120, 1050-1052.	2.0	14
219	Association of D-dimer with Plaque Characteristics and Plasma Biomarkers of Oxidation-Specific Epitopes in Stable Subjects with Coronary Artery Disease. <i>Journal of Cardiovascular Translational Research</i> , 2018, 11, 221-229.	1.1	14
220	Elevated lipoprotein(a) and the risk of stroke in children, young adults, and the elderly. <i>European Heart Journal</i> , 2021, 42, 2197-2200.	1.0	14
221	Short-term regulation of hematopoiesis by lipoprotein(a) results in the production of pro-inflammatory monocytes. <i>International Journal of Cardiology</i> , 2020, 315, 81-85.	0.8	13
222	Effect of bariatric surgery on plasma levels of oxidised phospholipids, biomarkers of oxidised LDL and lipoprotein(a). <i>Journal of Clinical Lipidology</i> , 2021, 15, 320-331.	0.6	13
223	PCSK9 Activity Is Potentiated Through HDL Binding. <i>Circulation Research</i> , 2021, 129, 1039-1053.	2.0	13
224	Concomitant coronary and multiple arch vessel stenoses in patients treated with external beam radiation: Pathophysiological basis and endovascular treatment. <i>Catheterization and Cardiovascular Interventions</i> , 2004, 62, 385-390.	0.7	12
225	Emerging approaches for imaging vulnerable plaques in patients. <i>Current Opinion in Biotechnology</i> , 2007, 18, 73-82.	3.3	12
226	Candidate biomarkers for the detection of coronary plaque destabilization and rupture. <i>Current Atherosclerosis Reports</i> , 2008, 10, 309-317.	2.0	11
227	The interconnection between lipoprotein(a), lipoprotein(a) cholesterol and true LDL-cholesterol in the diagnosis of familial hypercholesterolemia. <i>Current Opinion in Lipidology</i> , 2020, 31, 305-312.	1.2	11
228	Treatment of ischemic stroke complicating cardiac catheterization with systemic thrombolytic therapy. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 364-368.	0.7	10
229	Estrogen-Eluting Stents. <i>Journal of Cardiovascular Translational Research</i> , 2009, 2, 240-244.	1.1	10
230	The Prevalence of Lipoprotein(a) Measurement and Degree of Elevation Among 2710 Patients With Calcific Aortic Valve Stenosis in an Academic Echocardiography Laboratory Setting. <i>Angiology</i> , 2017, 68, 795-798.	0.8	10
231	A Neutralizing Antibody Targeting Oxidized Phospholipids Promotes Bone Anabolism in Chow-Fed Young Adult Mice. <i>Journal of Bone and Mineral Research</i> , 2020, 36, 170-185.	3.1	10
232	Development and validation of an isoform-independent monoclonal antibody-based ELISA for measurement of lipoprotein(a). <i>Journal of Lipid Research</i> , 2022, 63, 100239.	2.0	10
233	High-Density Lipoproteins Are the Main Carriers of PCSK9 in the Circulation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 1495-1497.	1.2	9
234	Lipoprotein(A) with An Intact Lysine Binding Site Protects the Retina From an Age-Related Macular Degeneration Phenotype in Mice (An American Ophthalmological Society Thesis). <i>Transactions of the American Ophthalmological Society</i> , 2015, 113, T5.	1.4	9

#	ARTICLE	IF	CITATIONS
235	Trends in testing and prevalence of elevated Lp(a) among patients with aortic valve stenosis. <i>Atherosclerosis</i> , 2022, 349, 144-150.	0.4	9
236	Oxidized phospholipids on apolipoprotein B-100 versus plasminogen and risk of coronary heart disease in the PROCARDIS study. <i>Atherosclerosis</i> , 2022, 354, 15-22.	0.4	9
237	PCSK9 loss-of-function variants and Lp(a) phenotypes among black US adults. <i>Journal of Lipid Research</i> , 2019, 60, 1946-1952.	2.0	8
238	Generation and characterization of LPA-KIV9, a murine monoclonal antibody binding a single site on apolipoprotein (a). <i>Journal of Lipid Research</i> , 2020, 61, 1263-1270.	2.0	8
239	Relationship of lipoprotein-associated apolipoprotein C-III with lipid variables and coronary artery disease risk: The EPIC-Norfolk prospective population study. <i>Journal of Clinical Lipidology</i> , 2018, 12, 1493-1501.e11.	0.6	7
240	A monoclonal antibody to assess oxidized cholesteryl esters associated with apoAI and apoB-100 lipoproteins in human plasma. <i>Journal of Lipid Research</i> , 2019, 60, 436-445.	2.0	7
241	Renal artery plaque composition is associated with changes in renal frame count following renal artery stenting. <i>Journal of Invasive Cardiology</i> , 2011, 23, 227-31.	0.4	7
242	Generation of cardio-protective antibodies after pneumococcal polysaccharide vaccine: Early results from a randomised controlled trial. <i>Atherosclerosis</i> , 2022, 346, 68-74.	0.4	7
243	Interventional hepatic apoC-III knockdown improves atherosclerotic plaque stability and remodeling by triglyceride lowering. <i>JCI Insight</i> , 2022, 7, .	2.3	7
244	Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial. <i>Atherosclerosis</i> , 2017, 260, 1-7.	0.4	6
245	Lipoprotein(a) in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>Angiology</i> , 2019, 70, 332-336.	0.8	6
246	Association of lipoprotein(a) with intrinsic and on-clopidogrel platelet reactivity. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, 53, 1-9.	1.0	6
247	PCSK9 Inhibition and Oxidized Phospholipids. <i>Journal of the American College of Cardiology</i> , 2021, 78, 1288-1289.	1.2	6
248	The Clinical Emergence of Optical Coherence Tomography. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1090-1092.	1.2	5
249	Catheter-induced Vasospasm of Both the Right External Iliac and Right Coronary Arteries During Coronary Angiography. <i>International Journal of Cardiovascular Imaging</i> , 2005, 21, 481-485.	0.7	4
250	Lipoprotein oxidation biomarkers for cardiovascular risk: what does the future hold?. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 399-402.	0.6	4
251	Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention. <i>Journal of Thrombosis and Thrombolysis</i> , 2001, 11, 217-221.	1.0	3
252	Retrieval of a detached transseptal sheath tip from a right pulmonary artery branch following catheter ablation. <i>Catheterization and Cardiovascular Interventions</i> , 2015, 86, 1131-1135.	0.7	3

#	ARTICLE	IF	CITATIONS
253	Plasma Levels of Advanced Glycation End Products Are Related to the Clinical Presentation and Angiographic Severity of Symptomatic Lower Extremity Peripheral Arterial Disease. <i>International Journal of Angiology</i> , 2016, 25, 044-053.	0.2	3
254	Elevated Lp(a) and Abdominal Aortic Aneurysm. <i>Angiology</i> , 2017, 68, 96-98.	0.8	3
255	In Search of Patients With Elevated Lp(a). <i>Journal of the American College of Cardiology</i> , 2019, 73, 1040-1042.	1.2	3
256	Lipoproteins and Oxidation. , 2006, , 17-48.		3
257	Longitudinal Assessment of Lipoprotein(a) Levels in Perinatally HIV-Infected Children and Adolescents. <i>Viruses</i> , 2021, 13, 2067.	1.5	3
258	Elevated Lipoprotein(a) in Perinatally HIV-Infected Children Compared With Healthy Ethnicity-Matched Controls. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz301.	0.4	3
259	Lipoprotein(a) and CT Angiography. <i>Journal of the American College of Cardiology</i> , 2022, 79, 234-237.	1.2	3
260	Lipoprotein(a) and Coronary Calcium. <i>Journal of the American College of Cardiology</i> , 2022, 79, 769-771.	1.2	3
261	Lipoprotein Oxidation and Modification. , 2009, , 93-110.		2
262	Highlights of the Year in JACC 2013. <i>Journal of the American College of Cardiology</i> , 2014, 63, 570-602.	1.2	2
263	Lipoprotein Apheresis and Acute Reduction of Arterial Inflammation. <i>Journal of the American College of Cardiology</i> , 2014, 64, 1427-1429.	1.2	2
264	HDL-C, ABCA1-mediated cholesterol efflux, and lipoprotein(a): insights into a potential novel physiologic role of lipoprotein(a). <i>Journal of Lipid Research</i> , 2015, 56, 1241-1244.	2.0	2
265	Ancient Remedy for a Modern Disease. <i>JACC Basic To Translational Science</i> , 2020, 5, 50-52.	1.9	2
266	Always Present, But Now Rediscovered. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 2069-2072.	1.1	2
267	Rapid progression of common femoral artery stenosis leading to development of ischemic foot ulcer following repeated ipsilateral arterial access. <i>Catheterization and Cardiovascular Interventions</i> , 2005, 66, 487-490.	0.7	1
268	Highlights of the Year in JACC 2008. <i>Journal of the American College of Cardiology</i> , 2009, 53, 373-398.	1.2	1
269	Clinical Trial Report: The Presence and Rupture of Vulnerable Plaques in the Peripheral Circulation. <i>Current Cardiovascular Imaging Reports</i> , 2010, 3, 187-189.	0.4	1
270	Highlights of the Year in JACC 2010. <i>Journal of the American College of Cardiology</i> , 2011, 57, 480-514.	1.2	1

#	ARTICLE	IF	CITATIONS
271	Successful treatment of in-stent restenosis of a covered stent graft with a paclitaxel-eluting stent. <i>Journal of Cardiology Cases</i> , 2011, 4, e13-e15.	0.2	1
272	Highlights of the Year in JACC 2011. <i>Journal of the American College of Cardiology</i> , 2012, 59, 503-537.	1.2	1
273	Highlights of the Year in JACC 2012. <i>Journal of the American College of Cardiology</i> , 2013, 61, 357-385.	1.2	1
274	The role of lipoprotein(a) in progression of renal disease: Causality or reverse causality?. <i>Journal of Diabetes and Its Complications</i> , 2016, 30, 755-757.	1.2	1
275	Abstract 3625: Targeted Ultra-Small Iron Oxide Particles for In Vivo MR Detection of Atherosclerotic Lesions Using Antibodies against Oxidized Low Density Lipoprotein. <i>Circulation</i> , 2008, 118, .	1.6	1
276	Spontaneous recanalization of a completely occluded saphenous vein graft two months following acute myocardial infarction with persistent one year patency. <i>Journal of Thrombosis and Thrombolysis</i> , 2009, 28, 101-105.	1.0	0
277	Tracking Oxidatively Stressed Cardiac Stem Cells With Molecular Imaging. <i>JACC: Cardiovascular Imaging</i> , 2013, 6, 803-805.	2.3	0
278	Glucose Control in Patients Undergoing PPCI. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 398-400.	1.1	0
279	Nuclear imaging of the vulnerable plaque. , 2007, , 303-312.		0
280	Effects of low-fat, high-carbohydrate diet on plasma lipoprotein(a) and oxidized phospholipids. <i>FASEB Journal</i> , 2010, 24, 1b365.	0.2	0
281	Molecular Imaging of Oxidation-Specific Epitopes to Detect High-Risk Atherosclerotic Plaques. , 2015, , 121-154.		0
282	Abstract 21: B-1b Cells Secrete Atheroprotective IgM and Attenuate Atherosclerosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2015, 35, .	1.1	0